Genetic Variants in Linear Localized Scleroderma

Not Applicable

Completed

• Conditions: Morphea
• Interventions: Other: skin biopsy

• Registration Number: NCT02222038
• Lead Sponsor: University Children's Hospital, Zurich

Brief Summary

The purpose of this study is to investigate the genetic architecture of Linear Localized Scleroderma (LLS) (linear morphea) by whole exome sequencing.

Detailed Description

At present the etiology of LLS is unknown, but a genetic background is suspected. Although LLS clearly classifies as a mosaic disorder, its genetics and protein machinery remain to be understood.

We are going to use a tailored approach to identify the genetic factors of LLS. In the first phase of the study we will investigate the genetic architecture in LLS. WES will analyze whole protein coding DNA in skin samples of 50 consenting LLS patient. The aim is to identify the key genes associated with LLS. In the second phase of the study subsequent functional experiments will be performed. Based on the identified candidate genes, knockdown and overexpression models will be created with relevant cell lines (fibroblasts) to identify the biological consequences and confirm the functional relevance of the identified genetic mutations in LLS. Further the protein network active in LLS will be investigated (proteomic analysis).

The described basic genetic studies combined with functional experiments will lay the groundwork for treatment trials to provide possibly novel treatment options.

Study Timeline

• Study First Submitted: 2014-07-21
• Study Start: 2014-08
• Study First Submitted QC: 2014-08-20
• Study First Posted: 2014-08-21
• Primary Completion: 2017-10
• Study Completion: 2017-10-31
• Status Verified: 2020-11
• Last Update Submitted: 2020-11-09
• Last Update Posted: 2020-11-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Male or female subjects ≥ 5 years of age with well phenotyped LLS
• Affecting their head and / or face "termed " en coup de sabre " type LLS or Hemiatrophia faciei or Parry-Romberg syndrome, with or without therapy
• Affecting any site of the body except the head or face, with or without therapy

Exclusion Criteria

• Patients with signs of systemic scleroderma
• Patients with localized scleroderma (morphea) other than the linear type ("plaque-type", "morphea profunda", "generalized morphea") Patients with diagnosed gadolinium induced scleroderma Patients with post-irradiation scleroderma Patients with missing consent

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
skin biopsy	skin biopsy	4mm punch biopsy

Primary Outcome Measures

Name	Time	Method
number of key genes /number of mutations in LLS (localized linear scleroderma)	24-30 months

Secondary Outcome Measures

Name	Time	Method
the investigation of the protein network of the identified key genes in order to assess their biological function and their relevance in the pathogenesis of LLS.	24-30 months

Trial Locations

Locations (2)

University Children's Hospital, Department of Pediatric Dermatology; 🇨🇭 Zurich, Switzerland

University Hospital, Department of Dermatology; 🇨🇭 Zurich, Switzerland